Published in Hepatology on March 01, 2007
Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J Virol (2007) 3.83
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood (2009) 1.35
Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology (2010) 1.28
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J Biomed Biotechnol (2011) 1.22
Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models. J Infect Dis (2010) 1.21
Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines (2009) 1.16
Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther (2013) 1.15
Acute hepatitis C virus infection: a chronic problem. Hepatology (2008) 1.15
Emerging concepts in immunity to hepatitis C virus infection. J Clin Invest (2013) 1.12
Successful vaccination induces multifunctional memory T-cell precursors associated with early control of hepatitis C virus. Gastroenterology (2012) 1.12
Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A (2013) 1.10
Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol (2008) 1.05
Will there be a vaccine to prevent HCV infection? Semin Liver Dis (2014) 1.02
Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J Gastroenterol (2014) 0.98
Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther (2013) 0.96
Dendritic cells in hepatitis C infection: can they (help) win the battle? J Gastroenterol (2011) 0.94
Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. Inflamm Res (2010) 0.93
The frequency of CD127(+) hepatitis C virus (HCV)-specific T cells but not the expression of exhaustion markers predicts the outcome of acute HCV infection. J Virol (2013) 0.93
Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein booster. J Virol (2012) 0.92
Clearance of genotype 1b hepatitis C virus in chimpanzees in the presence of vaccine-induced E1-neutralizing antibodies. J Infect Dis (2011) 0.88
Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol (2016) 0.86
CD8(+) T-Cell Responses in Acute Hepatitis C Virus Infection. Front Immunol (2014) 0.83
Influence of HIV and HCV on T cell antigen presentation and challenges in the development of vaccines. Front Microbiol (2014) 0.83
Effect of dipterinyl calcium pentahydrate on hepatitis B virus replication in transgenic mice. J Transl Med (2010) 0.82
T-cell dysfunction and inhibitory receptors in hepatitis C virus infection. Immune Netw (2010) 0.80
Toll-like receptor 2 senses hepatitis C virus core protein but not infectious viral particles. J Innate Immun (2009) 0.80
Prophylactic and Therapeutic Vaccination against Hepatitis C Virus (HCV): Developments and Future Perspectives. Viruses (2009) 0.80
Enhanced virus-specific CD8+ T cell responses by Listeria monocytogenes-infected dendritic cells in the context of Tim-3 blockade. PLoS One (2014) 0.79
Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. World J Hepatol (2015) 0.78
Evolution to a chronic disease niche correlates with increased sensitivity to tryptophan availability for the obligate intracellular bacterium Chlamydia pneumoniae. J Bacteriol (2014) 0.77
Strong vaccine-induced CD8 T-cell responses have cytolytic function in a chimpanzee clearing HCV infection. PLoS One (2014) 0.77
Antiviral and Immunoregulatory Effects of Indoleamine-2,3-Dioxygenase in Hepatitis C Virus Infection. J Innate Immun (2015) 0.76
Functional differences in hepatitis C virus nonstructural (NS) 3/4A- and 5A-specific T cell responses. Sci Rep (2016) 0.75
Progress in the development of vaccines for hepatitis C virus infection. World J Gastroenterol (2015) 0.75
Changes in immune cell populations in the periphery and liver of GBV-B-infected and convalescent tamarins (Saguinus labiatus). Virus Res (2013) 0.75
Comparative Immunogenicity in Rabbits of the Polypeptides Encoded by the 5' Terminus of Hepatitis C Virus RNA. J Immunol Res (2015) 0.75
T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates. Gene Ther (2016) 0.75
Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol (2003) 9.09
A Toll-like receptor-independent antiviral response induced by double-stranded B-form DNA. Nat Immunol (2005) 7.94
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology (2003) 4.21
IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J Immunol (2003) 3.69
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology (2005) 2.93
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology (2006) 2.62
Severe acute respiratory syndrome coronavirus phylogeny: toward consensus. J Virol (2004) 2.61
SIVcpz in wild chimpanzees. Science (2002) 2.45
Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc Natl Acad Sci U S A (2005) 2.42
Characterization of functional hepatitis C virus envelope glycoproteins. J Virol (2004) 2.40
Nidovirus transcription: how to make sense...? J Gen Virol (2006) 2.30
A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol (2003) 2.25
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol (2005) 2.19
Independent evolution of an antiviral TRIMCyp in rhesus macaques. Proc Natl Acad Sci U S A (2008) 2.15
Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14
Foci of endemic simian immunodeficiency virus infection in wild-living eastern chimpanzees (Pan troglodytes schweinfurthii). J Virol (2003) 2.12
Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J Exp Med (2009) 2.10
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol (2010) 1.96
Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci U S A (2002) 1.85
Immunology of hepatitis B infection. Lancet Infect Dis (2002) 1.75
Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol (2002) 1.67
IL-17-induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J Exp Med (2014) 1.67
Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl (2013) 1.66
The impact of dual viral infection in infants admitted to a pediatric intensive care unit associated with severe bronchiolitis. Pediatr Infect Dis J (2008) 1.65
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential? Curr Opin Biotechnol (2004) 1.58
Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy. J Virol (2005) 1.54
Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2. J Virol (2005) 1.53
Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. Proc Natl Acad Sci U S A (2004) 1.53
Detection of functionally altered hepatitis C virus-specific CD4 T cells in acute and chronic hepatitis C. Hepatology (2003) 1.52
Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses. J Virol (2007) 1.50
An RNA pseudoknot is required for production of yellow fever virus subgenomic RNA by the host nuclease XRN1. J Virol (2010) 1.49
The immunoregulatory role of CD244 in chronic hepatitis B infection and its inhibitory potential on virus-specific CD8+ T-cell function. Hepatology (2010) 1.48
The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood (2008) 1.48
Mixed respiratory virus infections. J Clin Virol (2008) 1.46
Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology (2011) 1.44
Group 2 coronaviruses prevent immediate early interferon induction by protection of viral RNA from host cell recognition. Virology (2007) 1.44
Hepatitis C virus glycoproteins mediate low pH-dependent membrane fusion with liposomes. J Biol Chem (2005) 1.41
C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem (2004) 1.41
Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord (2003) 1.41
Evidence for an ancient selective sweep in the MHC class I gene repertoire of chimpanzees. Proc Natl Acad Sci U S A (2002) 1.39
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology (2005) 1.38
Extensive sharing of MHC class II alleles between rhesus and cynomolgus macaques. Immunogenetics (2006) 1.36
Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog (2009) 1.36
The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol (2009) 1.36
Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine (2003) 1.34
Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol (2013) 1.34
Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology (2005) 1.33
A viral discovery methodology for clinical biopsy samples utilising massively parallel next generation sequencing. PLoS One (2011) 1.32
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. J Immunol (2012) 1.30
Cross-priming of cytotoxic T cells dictates antigen requisites for modified vaccinia virus Ankara vector vaccines. J Virol (2007) 1.30
Rhesus macaque TRIM5 alleles have divergent antiretroviral specificities. J Virol (2008) 1.29
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 1.29
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
HCV and oxidative stress in the liver. Viruses (2013) 1.28
Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One (2010) 1.26
Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J Virol (2008) 1.26
Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology (2008) 1.26
HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res (2004) 1.26
Evolutionary stability of MHC class II haplotypes in diverse rhesus macaque populations. Immunogenetics (2003) 1.26
An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One (2011) 1.24
Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol (2005) 1.24
The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus. J Biol Chem (2007) 1.21
Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry. J Virol (2005) 1.21
Seroreactivity to epidermodysplasia verruciformis-related human papillomavirus types is associated with nonmelanoma skin cancer. Cancer Res (2003) 1.20
The role of interleukin-22 in hepatitis C virus infection. Cytokine (2008) 1.20
Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol (2002) 1.19
Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. Blood (2002) 1.19
Detection and characterization of two chimpanzee polyomavirus genotypes from different subspecies. Virol J (2010) 1.19
Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas. J Natl Cancer Inst (2009) 1.19
Construction and isolation of recombinant MVA. Methods Mol Biol (2004) 1.19
Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol (2005) 1.18
Genetic basis for clinical response to CTLA-4 blockade. N Engl J Med (2015) 1.18
Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1. J Infect Dis (2007) 1.18
Infection of human dendritic cells with recombinant vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology (2006) 1.18
Retinoic acid induces blood-brain barrier development. J Neurosci (2013) 1.17
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 1.16